HeartBeam Provides Update on Regulatory Path Following FDA Decision on 12-Lead ECG Synthesis Software Application

Core Insights - HeartBeam has provided an update regarding its regulatory path following the FDA's decision on its 12-lead ECG synthesis software application [1] Regulatory Update - The company is actively working on addressing the feedback received from the FDA to enhance its software application [1] - HeartBeam aims to ensure compliance with regulatory standards to facilitate the approval process [1] Future Plans - The company is focused on advancing its technology and plans to submit additional data to the FDA to support its application [1] - HeartBeam is committed to improving patient care through innovative cardiac monitoring solutions [1]